<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36626364</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases.</ArticleTitle><Pagination><StartPage>e0011001</StartPage><MedlinePgn>e0011001</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0011001</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0011001</ELocationID><Abstract><AbstractText Label="BACKGROUND">Enterovirus A71 (EV-A71) is an important causative agent of hand-foot-and-mouth disease (HFMD) associated with enormous healthcare and socioeconomic burden. Although a range of studies about EV-A71 pathogenesis have been well described, the underlying molecular mechanism in terms of innate immune response is still not fully understood, especially the roles of TANK-binding kinase 1 (TBK1) and interferon-regulatory factor 3 (IRF3).</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS">Here, we applied TBK1 inhibitor and IRF3 agonist, for the first time, to evaluate the antiviral activities of TBK1 and IRF3 in vivo. We found that, through regulating EV-A71-induced type I interferon (IFN) response, IRF3 agonist effectively alleviated EV-A71-induced illness, while TBK1 inhibitor aggravated disease progression. In addition, EV-A71 replication was suppressed in EVA-71-infected mice administrated with IRF3 agonist. On the other hand, more severe pathological alterations of neuronal degeneration, muscle fiber breaks, fractured or fused alveolar walls, and diffuse congestion occurred in EVA-71-infected mice treated with TBK1 inhibitor administration. Furthermore, we determined the concentrations of interleukin (IL)-6, tumor necrosis factor-alpha (TNF-&#x3b1;), IL-1&#x3b2;, monocyte chemotactic protein-1 (MCP-1), and IL-10 in both lungs and brains of mice and found that TBK1 inhibitor promoted EV-A71-induced inflammatory response, while IRF3 agonist alleviated it, which was consistent with clinical manifestations and pathological alterations.</AbstractText><AbstractText Label="CONCLUSIONS">Collectively, our findings suggest that TBK1 and IRF3 are potential therapeutic targets in EV-A71-induced illness.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Ji et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Wangquan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henan Key Laboratory of Molecular Medicine, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Tiantian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shuaiyin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yuefei</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5084-5859</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Guangcai</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henan Key Laboratory of Molecular Medicine, Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>10</Day><Hour>13</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36626364</ArticleId><ArticleId IdType="pmc">PMC9831319</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0011001</ArticleId><ArticleId IdType="pii">PNTD-D-22-00284</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mao QY, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert review of vaccines. 2016;15(5):599&#x2013;606. Epub 2016/01/07. doi: 10.1586/14760584.2016.1138862 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li Y. Recent Progress on Functional Genomics Research of Enterovirus 71. Virologica Sinica. 2019;34(1):9&#x2013;21. Epub 2018/12/16. doi: 10.1007/s12250-018-0071-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-018-0071-9</ArticleId><ArticleId IdType="pmc">PMC6420560</ArticleId><ArticleId IdType="pubmed">30552635</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778&#x2013;90. Epub 2010/10/22. doi: 10.1016/S1473-3099(10)70194-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim ZQ, Ng QY, Ng JWQ, Mahendran V, Alonso S. Recent progress and challenges in drug development to fight hand, foot and mouth disease. Expert opinion on drug discovery. 2020;15(3):359&#x2013;71. Epub 2019/09/01. doi: 10.1080/17460441.2019.1659241 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2019.1659241</ArticleId><ArticleId IdType="pubmed">31470744</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Zhang R, Wu W, Duan G. Innate Immunity Evasion by Enteroviruses Linked to Epidemic Hand-Foot-Mouth Disease. Frontiers in microbiology. 2018;9:2422. Epub 2018/10/24. doi: 10.3389/fmicb.2018.02422</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.02422</ArticleId><ArticleId IdType="pmc">PMC6186807</ArticleId><ArticleId IdType="pubmed">30349526</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasti M, Khanbabaei H, Teimoori A. An update on enterovirus 71 infection and interferon type I response. Rev Med Virol. 2019;29(1):e2016. Epub 2018/11/01. doi: 10.1002/rmv.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2016</ArticleId><ArticleId IdType="pmc">PMC7169063</ArticleId><ArticleId IdType="pubmed">30378208</ArticleId></ArticleIdList></Reference><Reference><Citation>McNab F, Mayer-Barber K, Sher A, Wack A, O&#x2019;Garra A. Type I interferons in infectious disease. Nature reviews Immunology. 2015;15(2):87&#x2013;103. Epub 2015/01/24. doi: 10.1038/nri3787</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3787</ArticleId><ArticleId IdType="pmc">PMC7162685</ArticleId><ArticleId IdType="pubmed">25614319</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16(4):343&#x2013;53. Epub 2015/03/20. doi: 10.1038/ni.3123</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3123</ArticleId><ArticleId IdType="pmc">PMC4507498</ArticleId><ArticleId IdType="pubmed">25789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clinical microbiology reviews. 2009;22(2):240&#x2013;73, Table of Contents. Epub 2009/04/16. doi: 10.1128/CMR.00046-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00046-08</ArticleId><ArticleId IdType="pmc">PMC2668232</ArticleId><ArticleId IdType="pubmed">19366914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011;30(1):16&#x2013;34. Epub 2011/01/18. doi: 10.3109/08830185.2010.529976 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08830185.2010.529976</ArticleId><ArticleId IdType="pubmed">21235323</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Zhang R, Wu W, Duan G. Antiviral and Inflammatory Cellular Signaling Associated with Enterovirus 71 Infection. Viruses. 2018;10(4). Epub 2018/03/31. doi: 10.3390/v10040155</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10040155</ArticleId><ArticleId IdType="pmc">PMC5923449</ArticleId><ArticleId IdType="pubmed">29597291</ArticleId></ArticleIdList></Reference><Reference><Citation>Oganesyan G, Saha SK, Guo B, He JQ, Shahangian A, Zarnegar B, et al.. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature. 2006;439(7073):208&#x2013;11. Epub 2005/11/25. doi: 10.1038/nature04374 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04374</ArticleId><ArticleId IdType="pubmed">16306936</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SS, Lee KG, Chin CS, Ng SK, Pereira NA, Xu S, et al.. DOK3 is required for IFN-beta production by enabling TRAF3/TBK1 complex formation and IRF3 activation. J Immunol. 2014;193(2):840&#x2013;8. Epub 2014/06/15. doi: 10.4049/jimmunol.1301601 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301601</ArticleId><ArticleId IdType="pubmed">24929003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferies CA. Regulating IRFs in IFN Driven Disease. Front Immunol. 2019;10:325. Epub 2019/04/16. doi: 10.3389/fimmu.2019.00325</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00325</ArticleId><ArticleId IdType="pmc">PMC6449421</ArticleId><ArticleId IdType="pubmed">30984161</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006;25(3):349&#x2013;60. Epub 2006/09/19. doi: 10.1016/j.immuni.2006.08.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.08.009</ArticleId><ArticleId IdType="pubmed">16979567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingle H, Peterson ST, Baldridge MT. Distinct Effects of Type I and III Interferons on Enteric Viruses. Viruses. 2018;10(1). Epub 2018/01/25. doi: 10.3390/v10010046</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10010046</ArticleId><ArticleId IdType="pmc">PMC5795459</ArticleId><ArticleId IdType="pubmed">29361691</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Current opinion in virology. 2011;1(6):519&#x2013;25. Epub 2012/02/14. doi: 10.1016/j.coviro.2011.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2011.10.008</ArticleId><ArticleId IdType="pmc">PMC3274382</ArticleId><ArticleId IdType="pubmed">22328912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W. Negative regulation of TBK1-mediated antiviral immunity. FEBS letters. 2013;587(6):542&#x2013;8. Epub 2013/02/12. doi: 10.1016/j.febslet.2013.01.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2013.01.052</ArticleId><ArticleId IdType="pmc">PMC7094513</ArticleId><ArticleId IdType="pubmed">23395611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Zhao W. TANK-binding kinase 1 as a novel therapeutic target for viral diseases. Expert Opin Ther Targets. 2019;23(5):437&#x2013;46. Epub 2019/04/02. doi: 10.1080/14728222.2019.1601702 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2019.1601702</ArticleId><ArticleId IdType="pubmed">30932713</ArticleId></ArticleIdList></Reference><Reference><Citation>Petro TM. IFN Regulatory Factor 3 in Health and Disease. Journal of immunology (Baltimore, Md: 1950). 2020;205(8):1981&#x2013;9. Epub 2020/10/07. doi: 10.4049/jimmunol.2000462 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000462</ArticleId><ArticleId IdType="pubmed">33020188</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathinayake PS, Hsu AC, Wark PA. Innate Immunity and Immune Evasion by Enterovirus 71. Viruses. 2015;7(12):6613&#x2013;30. Epub 2015/12/24. doi: 10.3390/v7122961</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122961</ArticleId><ArticleId IdType="pmc">PMC4690884</ArticleId><ArticleId IdType="pubmed">26694447</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KR, Ling P. Interplays between Enterovirus A71 and the innate immune system. J Biomed Sci. 2019;26(1):95. Epub 2019/12/04. doi: 10.1186/s12929-019-0596-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0596-8</ArticleId><ArticleId IdType="pmc">PMC6886175</ArticleId><ArticleId IdType="pubmed">31787104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SH, Wang K, Zhao K, Hua SC, Du J. The Structure, Function, and Mechanisms of Action of Enterovirus Non-structural Protein 2C. Front Microbiol. 2020;11:615965. Epub 2021/01/01. doi: 10.3389/fmicb.2020.615965</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.615965</ArticleId><ArticleId IdType="pmc">PMC7767853</ArticleId><ArticleId IdType="pubmed">33381104</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HI, Weng KF, Shih SR. Viral and host factors that contribute to pathogenicity of enterovirus 71. Future Microbiol. 2012;7(4):467&#x2013;79. Epub 2012/03/24. doi: 10.2217/fmb.12.22 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.12.22</ArticleId><ArticleId IdType="pubmed">22439724</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Liu X, Ma Y, Sun Z, Yang Y, Jin Q, et al.. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. Journal of virology. 2010;84(16):8051&#x2013;61. Epub 2010/06/04. doi: 10.1128/JVI.02491-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02491-09</ArticleId><ArticleId IdType="pmc">PMC2916543</ArticleId><ArticleId IdType="pubmed">20519382</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Langereis MA, Lork M, Nguyen M, Hato SV, Lanke K, et al.. Enterovirus 2Apro targets MDA5 and MAVS in infected cells. Journal of virology. 2014;88(6):3369&#x2013;78. Epub 2014/01/07. doi: 10.1128/JVI.02712-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02712-13</ArticleId><ArticleId IdType="pmc">PMC3957915</ArticleId><ArticleId IdType="pubmed">24390337</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J, Zheng Y, Mo J, Wang W, Luo Z, Li Y, et al.. Sox4 represses host innate immunity to facilitate pathogen infection by hijacking the TLR signaling networks. Virulence. 2021;12(1):704&#x2013;22. Epub 2021/02/02. doi: 10.1080/21505594.2021.1882775</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2021.1882775</ArticleId><ArticleId IdType="pmc">PMC7894441</ArticleId><ArticleId IdType="pubmed">33517839</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Han C, Li T, Li N, Cao X. The methyltransferase PRMT6 attenuates antiviral innate immunity by blocking TBK1-IRF3 signaling. Cell Mol Immunol. 2019;16(10):800&#x2013;9. Epub 2018/07/06. doi: 10.1038/s41423-018-0057-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-018-0057-4</ArticleId><ArticleId IdType="pmc">PMC6804946</ArticleId><ArticleId IdType="pubmed">29973649</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, et al.. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science. 2015;347(6227):aaa2630. Epub 2015/02/01. doi: 10.1126/science.aaa2630 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa2630</ArticleId><ArticleId IdType="pubmed">25636800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B, Shu C, Gao X, Sankaran B, Du F, Shelton CL, et al.. Structural basis for concerted recruitment and activation of IRF-3 by innate immune adaptor proteins. Proc Natl Acad Sci U S A. 2016;113(24):E3403&#x2013;12. Epub 2016/06/16. doi: 10.1073/pnas.1603269113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1603269113</ArticleId><ArticleId IdType="pmc">PMC4914169</ArticleId><ArticleId IdType="pubmed">27302953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakari R, Matsumiya T, Xing F, Yoshida H, Hayakari M, Imaizumi T. Critical Role of IRF-3 in the Direct Regulation of dsRNA-Induced Retinoic Acid-Inducible Gene-I (RIG-I) Expression. PLoS One. 2016;11(9):e0163520. Epub 2016/09/24. doi: 10.1371/journal.pone.0163520</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0163520</ArticleId><ArticleId IdType="pmc">PMC5035021</ArticleId><ArticleId IdType="pubmed">27662626</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Chen S, Zhang W, Zhang C, Sun T, Du Y, et al.. MicroRNA-628-5p Facilitates Enterovirus 71 Infection by Suppressing TRAF3 Signaling. Cell Mol Immunol. 2021;18(5):1320&#x2013;2. Epub 2020/05/14. doi: 10.1038/s41423-020-0453-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0453-4</ArticleId><ArticleId IdType="pmc">PMC8093227</ArticleId><ArticleId IdType="pubmed">32398803</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Zhang C, Zhang R, Ren J, Chen S, Sui M, et al.. Pulmonary edema following central nervous system lesions induced by a non- mouse-adapted EV71 strain in neonatal BALB/c mice. Virol J. 2017;14(1):243. Epub 2017/12/29. doi: 10.1186/s12985-017-0911-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-017-0911-5</ArticleId><ArticleId IdType="pmc">PMC5745784</ArticleId><ArticleId IdType="pubmed">29282065</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ M H. A simple method of estimating 50 percent end-points. Am J Epidemiol. 1938:27:493&#x2013;7.</Citation></Reference><Reference><Citation>Muvaffak A, Pan Q, Yan H, Fernandez R, Lim J, Dolinski B, et al.. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol Cancer Res. 2014;12(7):1055&#x2013;66. Epub 2014/04/23. doi: 10.1158/1541-7786.MCR-13-0642 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.MCR-13-0642</ArticleId><ArticleId IdType="pubmed">24752990</ArticleId></ArticleIdList></Reference><Reference><Citation>Probst P, Grigg JB, Wang M, Munoz E, Loo YM, Ireton RC, et al.. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response. Vaccine. 2017;35(15):1964&#x2013;71. Epub 2017/03/11. doi: 10.1016/j.vaccine.2017.01.053 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.01.053</ArticleId><ArticleId IdType="pubmed">28279563</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Dong Z, Li J, Carr MJ, Zhuang D, Wang J, et al.. Protective Efficacies of Formaldehyde-Inactivated Whole-Virus Vaccine and Antivirals in a Murine Model of Coxsackievirus A10 Infection. J Virol. 2017;91(13). Epub 2017/04/21. doi: 10.1128/JVI.00333-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00333-17</ArticleId><ArticleId IdType="pmc">PMC5469256</ArticleId><ArticleId IdType="pubmed">28424287</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao S, Guan J, Chen M, Wang W, Li C, Wang Y, et al.. Targeting IRF3 as a YAP agonist therapy against gastric cancer. The Journal of experimental medicine. 2018;215(2):699&#x2013;718. Epub 2018/01/18. doi: 10.1084/jem.20171116</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171116</ArticleId><ArticleId IdType="pmc">PMC5789414</ArticleId><ArticleId IdType="pubmed">29339449</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun LL, Wang JK, Cui XQ, Hao SB, Li J, Zhao L, et al.. Association of viral replication capacity with the pathogenicity of enterovirus 71. Virus research. 2014;189:1&#x2013;7. Epub 2014/05/06. doi: 10.1016/j.virusres.2014.04.014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.04.014</ArticleId><ArticleId IdType="pubmed">24792876</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C, Li Y, Zhou Y, Liang L, Turtle L, Wang F, et al.. Enterovirus genomic load and disease severity among children hospitalised with hand, foot and mouth disease. EBioMedicine. 2020;62:103078. Epub 2020/11/09. doi: 10.1016/j.ebiom.2020.103078</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.103078</ArticleId><ArticleId IdType="pmc">PMC7653080</ArticleId><ArticleId IdType="pubmed">33161231</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordey S, Petty TJ, Schibler M, Martinez Y, Gerlach D, van Belle S, et al.. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog. 2012;8(7):e1002826. Epub 2012/08/23. doi: 10.1371/journal.ppat.1002826</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002826</ArticleId><ArticleId IdType="pmc">PMC3406088</ArticleId><ArticleId IdType="pubmed">22910880</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Osorio JE. In Vivo Imaging with Bioluminescent Enterovirus 71 Allows for Real-Time Visualization of Tissue Tropism and Viral Spread. J Virol. 2017;91(5). Epub 2016/12/16. doi: 10.1128/JVI.01759-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01759-16</ArticleId><ArticleId IdType="pmc">PMC5309956</ArticleId><ArticleId IdType="pubmed">27974562</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HI, Lin JY, Chen SH. EV71 Infection Induces IFN&#x3b2; Expression in Neural Cells. Viruses. 2019;11(12). Epub 2019/12/11. doi: 10.3390/v11121121</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11121121</ArticleId><ArticleId IdType="pmc">PMC6950376</ArticleId><ArticleId IdType="pubmed">31817126</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ML, Lee YP, Wang YF, Lei HY, Liu CC, Wang SM, et al.. Type I interferons protect mice against enterovirus 71 infection. J Gen Virol. 2005;86(Pt 12):3263&#x2013;9. Epub 2005/11/22. doi: 10.1099/vir.0.81195-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.81195-0</ArticleId><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Ennis J, Turner JD, Chu JJ. Single dose of an adenovirus vectored mouse interferon-&#x3b1; protects mice from lethal EV71 challenge. Antiviral research. 2016;134:207&#x2013;15. Epub 2016/09/14. doi: 10.1016/j.antiviral.2016.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.09.003</ArticleId><ArticleId IdType="pmc">PMC7113890</ArticleId><ArticleId IdType="pubmed">27623347</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Zhang X, Wang F, Wei H, Ma H, Sui M, et al.. Clinical Efficacy of Therapy with Recombinant Human Interferon &#x3b1;1b in Hand, Foot, and Mouth Disease with Enterovirus 71 Infection. PloS one. 2016;11(2):e0148907. Epub 2016/02/18. doi: 10.1371/journal.pone.0148907</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0148907</ArticleId><ArticleId IdType="pmc">PMC4755579</ArticleId><ArticleId IdType="pubmed">26882102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho BC, Yu IS, Lu LF, Rudensky A, Chen HY, Tsai CW, et al.. Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I interferon. Nat Commun. 2014;5:3344. Epub 2014/02/25. doi: 10.1038/ncomms4344 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4344</ArticleId><ArticleId IdType="pubmed">24561744</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung HC, Wang HC, Shih SR, Teng IF, Tseng CP, Hsu JT. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis. 2011;203(12):1784&#x2013;90. Epub 2011/05/04. doi: 10.1093/infdis/jir174 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir174</ArticleId><ArticleId IdType="pubmed">21536800</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang NX, Zou Y, Liang QH, Wang YE, Liu YL, Xu GQ, et al.. Anemoside B4 inhibits enterovirus 71 propagation in mice through upregulating 14-3-3 expression and type I interferon responses. Acta Pharmacol Sin. 2021. Epub 2021/07/30. doi: 10.1038/s41401-021-00733-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-021-00733-1</ArticleId><ArticleId IdType="pmc">PMC8976028</ArticleId><ArticleId IdType="pubmed">34321612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye N, Gong X, Pang LL, Gao WJ, Zhang YT, Li XL, et al.. Cytokine responses and correlations thereof with clinical profiles in children with enterovirus 71 infections. BMC Infect Dis. 2015;15:225. Epub 2015/06/11. doi: 10.1186/s12879-015-0965-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-0965-1</ArticleId><ArticleId IdType="pmc">PMC4461975</ArticleId><ArticleId IdType="pubmed">26058678</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Liu CC. Cytokine immunopathogenesis of enterovirus 71 brain stem encephalitis. Clinical &amp; developmental immunology. 2012;2012:876241. Epub 2012/09/08. doi: 10.1155/2012/876241</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/876241</ArticleId><ArticleId IdType="pmc">PMC3432373</ArticleId><ArticleId IdType="pubmed">22956971</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Huang Z, Huang M, Zeng J. Predicting Severe Enterovirus 71-Infected Hand, Foot, and Mouth Disease: Cytokines and Chemokines. Mediators Inflamm. 2020;2020:9273241. Epub 2020/02/25. doi: 10.1155/2020/9273241</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/9273241</ArticleId><ArticleId IdType="pmc">PMC7013319</ArticleId><ArticleId IdType="pubmed">32089650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Liu H, Wang L, Yang F, Hu Y, Ren X, et al.. Comparative study of the cytokine/chemokine response in children with differing disease severity in enterovirus 71-induced hand, foot, and mouth disease. PloS one. 2013;8(6):e67430. Epub 2013/07/11. doi: 10.1371/journal.pone.0067430</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067430</ArticleId><ArticleId IdType="pmc">PMC3696071</ArticleId><ArticleId IdType="pubmed">23840697</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Feng Z, Wang W, Chen Y, Cheng J, Meng J, et al.. Global cytokine/chemokine profile identifies potential progression prediction indicators in hand-foot-and-mouth disease patients with Enterovirus A71 infections. Cytokine. 2019;123:154765. Epub 2019/07/01. doi: 10.1016/j.cyto.2019.154765 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2019.154765</ArticleId><ArticleId IdType="pubmed">31255913</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths MJ, Ooi MH, Wong SC, Mohan A, Podin Y, Perera D, et al.. In enterovirus 71 encephalitis with cardio-respiratory compromise, elevated interleukin 1&#x3b2;, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis. The Journal of infectious diseases. 2012;206(6):881&#x2013;92. Epub 2012/07/26. doi: 10.1093/infdis/jis446 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis446</ArticleId><ArticleId IdType="pubmed">22829643</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Chen HL, Chen ZZ, Li J, Chen ZB. IL-10-592 polymorphism is associated with IL-10 expression and severity of enterovirus 71 infection in chinese children. J Clin Virol. 2017;95:42&#x2013;6. Epub 2017/08/28. doi: 10.1016/j.jcv.2017.08.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2017.08.005</ArticleId><ArticleId IdType="pubmed">28843383</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan G, Yang H, Shi L, Sun W, Sui M, Zhang R, et al.. Serum inflammatory cytokine levels correlate with hand-foot-mouth disease severity: a nested serial case-control study. PLoS One. 2014;9(11):e112676. Epub 2014/11/13. doi: 10.1371/journal.pone.0112676</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0112676</ArticleId><ArticleId IdType="pmc">PMC4229228</ArticleId><ArticleId IdType="pubmed">25391156</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Son M, Kang JH, Choi UY. Serum interleukin-6 levels as an indicator of aseptic meningitis among children with enterovirus 71-induced hand, foot and mouth disease. Postgrad Med. 2018;130(2):258&#x2013;63. Epub 2017/12/13. doi: 10.1080/00325481.2018.1416257 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00325481.2018.1416257</ArticleId><ArticleId IdType="pubmed">29231065</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Li S, Cai C, Liu J, Wang Y, Jiang Y, et al.. Characterization of inflammatory cytokine profiles in cerebrospinal fluid of hand, foot, and mouth disease children with enterovirus 71-related encephalitis in Hangzhou, Zhejiang, China. Medicine. 2019;98(52):e18464. Epub 2019/12/27. doi: 10.1097/MD.0000000000018464</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000018464</ArticleId><ArticleId IdType="pmc">PMC6946215</ArticleId><ArticleId IdType="pubmed">31876729</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun JF, Li HL, Sun BX. Correlation analysis on serum inflammatory cytokine level and neurogenic pulmonary edema for children with severe hand-foot-mouth disease. Eur J Med Res. 2018;23(1):21. Epub 2018/05/05. doi: 10.1186/s40001-018-0313-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-018-0313-1</ArticleId><ArticleId IdType="pmc">PMC5934863</ArticleId><ArticleId IdType="pubmed">29724230</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Li S, Cai C, Xu Y, Jiang Y, Chen Z. Cerebrospinal fluid chemokine patterns in children with enterovirus 71-related encephalitis. Scientific reports. 2018;8(1):1658. Epub 2018/01/28. doi: 10.1038/s41598-018-19988-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19988-6</ArticleId><ArticleId IdType="pmc">PMC5786096</ArticleId><ArticleId IdType="pubmed">29374213</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Yu CK, Wang JR, Su IJ, Liu CC. Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. The Journal of infectious diseases. 2008;198(7):1002&#x2013;6. Epub 2008/08/20. doi: 10.1086/591462 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/591462</ArticleId><ArticleId IdType="pubmed">18710325</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>